Key result
Molsidomine and its active metabolite SIN-1 demonstrated platelet suppressant and fibrinolytic activities in animals and humans, including shortening of euglobulin clot lysis time in humans.
Why the study?
Does molsidomine and its active metabolite SIN-1 affect platelet aggregation and fibrinolysis in humans and animal models?
Does molsidomine and its active metabolite SIN-1 affect platelet aggregation and fibrinolysis in humans and animal models?
Molsidomine and its metabolite SIN-1 demonstrate platelet suppressant and fibrinolytic activities through potentially different mechanisms, including the promotion of a PGI2-like substance.
Supports antithrombotic investigation of molsidomine; leaves open clinical adoption without randomized trials.
Molsidomine and its active metabolite SIN-1 were examined in humans and animals for platelet suppressant and fibrinolytic activities. Following oral administration of molsidomine at doses of 6 or 15 mg/kg to rabbits, their blood platelets in PRP ex vivo required higher threshold concentrations of ADP, AA and thrombin to be aggregated. Unlike molsidomine, SIN-1 when infused (10 and 20 micrograms/kg i.v.) into anaesthetized cats caused a release of a substance disaggregating platelet clumps which had adhered to blood superfused collagen strip. The appearance of this unstable disaggregating substance was prevented by the pretreatment of cats with aspirin (50 mg/kg i.v.). It is suggested that SIN-1 may promote formation of a PGI2-like substance. In humans shortening of euglobulin clot lysis time was observed 60 min after a single ingestion of 2 mg of molsidomine. This fibrinolytic effect of molsidomine was not abolished by the pretreatment of patients with aspirin. Neither molsidomine nor SIN-1 activated fibrinolysis in preformed euglobulin clots in vitro.
No takes yet. Share an insight, caveat, or question.
Basista et al. (1985) studied this question. Molsidomine and SIN-1 was evaluated on Platelet suppressant and fibrinolytic activities. Molsidomine and its active metabolite SIN-1 demonstrated platelet suppressant and fibrinolytic activities in animals and humans, including shortening of euglobulin clot lysis time in humans.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: